

Appln. Serial No. 10/590,435
Response May 9, 2011

- 2 -

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection consisting of peptide ANX (SEQ. ID. NO. 28), wherein X is any amino acid except cysteine, or a salt thereof.
2. (Previously presented) The antifibrillogenic agent of claim 1, wherein X is I or F.
3. (Previously presented) The antifibrillogenic agent of claim 1, wherein the peptide is ANF (SEQ. ID. NO. 24), or a salt thereof.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Previously presented) The antifibrillogenic agent of claim 1, wherein said amyloidosis is IAPP-related.
14. (Previously presented) The antifibrillogenic agent of claim 1, wherein said amyloidosis is type 1 or type 2 diabetes.
15. (Previously presented) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 1 in association with a pharmaceutically-acceptable carrier.
16. (Currently Amended) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim [9] 2 in association with a pharmaceutically-acceptable carrier.

Claims 17 – 63 (Canceled)

DOCS #10356087 v. 2

Appl. Serial No. 10/590,435
Response May 9, 2011

- 3 -

64. (Previously Presented) A composition for inhibiting amyloidosis and/or for cytoprotection, comprising a therapeutically-effective amount of the antifibrillogenic agent of claim 3 in association with a pharmaceutically-acceptable carrier.
65. (New)The antifibrillogenic agent of claim 2, wherein said amyloidosis is IAPP-related.
66. (New)The antifibrillogenic agent of claim 2, wherein said amyloidosis is type 1 or type 2 diabetes.
67. (New)The antifibrillogenic agent of claim 3, wherein said amyloidosis is IAPP-related.
68. (New)The antifibrillogenic agent of claim 3, wherein said amyloidosis is type 1 or type 2 diabetes.